An eight-year-old boy who had lost the ability to walk due to a rare, fatal genetic condition has regained mobility after receiving an experimental drug, in what doctors are calling a landmark medical breakthrough.
Diagnosed with HPDL deficiency, the child had rapidly deteriorated into a wheelchair-bound state within months, but thanks to compassionate-use approval from the U.S. FDA, a new therapy using 4-hydroxybenzoate (4-HB) has reversed his decline.
Once a lively runner and avid soccer player, the boy’s symptoms began in 2023 with increasing clumsiness and ankle stiffness.
By November, his condition had worsened significantly—he could no longer stand without support. Genetic tests at NYU Langone revealed mutations in the HPDL gene, which plays a crucial role in the body’s production of coenzyme Q10 (CoQ10), a vital antioxidant necessary for mitochondrial health.
While CoQ10 supplements exist, they are ineffective in cases like his because they cannot cross the blood-brain barrier. This meant his brain and nervous system were left vulnerable to progressive damage, resulting in spasticity, paralysis, and in severe cases, death.
The real breakthrough came from researchers at NYU, led by Dr. Michael Pacold, who identified that 4-HB, a small and hydrophilic molecule, could bypass the HPDL deficiency and successfully cross into the brain to restore CoQ10 production.
READ ALSO: Best time to walk for maximum health
In mouse models, 4-HB dramatically improved neurological function. Encouraged by these results, the boy’s medical team pursued emergency FDA clearance to try the drug in a human subject.
Starting in late 2023, the boy began receiving daily oral doses of 4-HB dissolved in water. The results were almost immediate. Within weeks, he was walking short distances again. By mid-2024, he had completed a four-mile hike in Central Park and even returned to go-karting. Although he cannot yet resume competitive sports, his day-to-day mobility and quality of life have been restored—without any serious side effects.
“This is the first successful human application of 4-HB therapy for HPDL deficiency,” said Dr. Claire Miller, one of the lead physicians on the case. “It’s a powerful example of how research and clinical urgency can align to deliver truly life-changing outcomes.”
While experts caution that one case does not establish safety or efficacy for the broader population, it marks a milestone for rare disease treatments. The therapy is now being prepared for broader clinical trials that will assess its effect on a wider group of patients with HPDL-related and other mitochondrial conditions.
Dr. Pacold emphasized the importance of basic science, stating that the breakthrough stemmed from years of NIH-funded research. The case illustrates how targeted, mechanism-based treatments can transform care for rare diseases that often receive little attention due to their complexity and small patient populations.
This child’s story is more than a medical miracle—it is a beacon of hope for families facing devastating diagnoses with no clear path forward.
Times Of India
